<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39312724</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Comment on "Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis".</ArticleTitle><Pagination><StartPage>2404290</StartPage><MedlinePgn>2404290</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2404290</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2404290</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharifan</LastName><ForeName>Amin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0571-5964</Identifier><AffiliationInfo><Affiliation>Department for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>doi: 10.1080/21645515.2023.2221146</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">antimicrobial stewardship</Keyword><Keyword MajorTopicYN="N">health policy</Keyword><Keyword MajorTopicYN="N">heterologous</Keyword><Keyword MajorTopicYN="N">letter</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>22</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39312724</ArticleId><ArticleId IdType="pmc">PMC11421839</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2404290</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang X, Xia J, Jin L, Wu Y, Zheng X, Cao X, Meng X, Li J, Zhu F.. Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: a systematic review and meta-analysis. Hum Vaccin Immunother. 2023;19(2):2221146. doi:10.1080/21645515.2023.2221146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2221146</ArticleId><ArticleId IdType="pmc">PMC10288895</ArticleId><ArticleId IdType="pubmed">37344370</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO director-general’s opening remarks at the media briefing – 5 May 2023. [accessed 2023 Sep
5]. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023.</Citation></Reference><Reference><Citation>Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21(6):361–2. doi:10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard JA, Hong V, Kim JS, Shaw SF, Lewin B, Takhar H, Lipsitch M, Tartof SY. Increased vaccine sensitivity of an emerging SARS-CoV-2 variant. Nat Commun. 2023;14(1):3854. doi:10.1038/s41467-023-39567-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39567-2</ArticleId><ArticleId IdType="pmc">PMC10310822</ArticleId><ArticleId IdType="pubmed">37386005</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J, Hachmann NP, Collier AY, Lasrado N, Mazurek CR, Patio RC, Powers O, Surve N, Theiler J, Korber B, et al. Substantial neutralization escape by SARS-CoV-2 omicron variants BQ.1.1 and XBB.1. N Engl J Med. 2023;388(7):662–4. doi:10.1056/NEJMc2214314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214314</ArticleId><ArticleId IdType="pmc">PMC9878581</ArticleId><ArticleId IdType="pubmed">36652339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifan A. COVID-19 and the functionality of antivirals: the day after tomorrow. Health Secur. 2022;20(3):270–1. doi:10.1089/hs.2022.0073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hs.2022.0073</ArticleId><ArticleId IdType="pubmed">35723880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A, et al. Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med. 2023;388(9):854–7. doi:10.1056/NEJMc2214916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214916</ArticleId><ArticleId IdType="pmc">PMC9891359</ArticleId><ArticleId IdType="pubmed">36734885</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Duan M, Wang X, Gao P, Zhao X, Xu K, Gao GF. Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer vaccines. N Engl J Med. 2023;388(12):1142–5. doi:10.1056/NEJMc2216233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2216233</ArticleId><ArticleId IdType="pmc">PMC10029362</ArticleId><ArticleId IdType="pubmed">36856580</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr EJ, Wu MY, Gahir J, Harvey R, Townsley H, Bailey C, Fowler AS, Dowgier G, Hobbs A, Herman L, et al. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous omicron infection. Lancet Infect Dis. 2023;23(7):781–4. doi:10.1016/S1473-3099(23)00289-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00289-X</ArticleId><ArticleId IdType="pmc">PMC10241485</ArticleId><ArticleId IdType="pubmed">37290472</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . WHO SAGE roadmap on uses of COVID-19 vaccines in the context of OMICRON and substantial population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when Omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, update: 21 January 2022, latest update: 30 March 2023. World Health Organization; 2023. https://iris.who.int/handle/10665/366671.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>